CYP3A4 and MDR mediated interactions in drug therapy

Clinical Research and Regulatory Affairs

Volumn 23, Issue 3-4, 2006, Pages 125-163

  Pal, Dhananjay ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Absorption; CYP3A4; Drug drug Interactions; Drug herbal Interactions; Metabolism; P gp; Pls and Recreational Drugs; Therapeutic Agents

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALDOSTERONE; AMITRIPTYLINE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; CARDIOVASCULAR AGENT; CELIPROLOL; CIMETIDINE; CISPLATIN; CYTOCHROME P450 3A4; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; ENFUVIRTIDE; GLYCOPROTEIN P; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INDINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; PACLITAXEL; QUINOLONE DERIVATIVE; RECREATIONAL DRUG; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG; VALSPODAR; VINBLASTINE; VINCRISTINE; ZIDOVUDINE;

CHRONIC MYELOID LEUKEMIA; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BINDING; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TRANSPORT; HUMAN; MYELOID LEUKEMIA; NONHUMAN; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33847166853     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.1080/10601330600961935     Document Type: Review

References (253)

1. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006; 78: 2131-2145.
2. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92:1295-302.
3. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385-427.
4. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci 1997; 94:4028-4033.
5. van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, van Meer G.MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996; 87:507-17.
6. Ruetz S, Gros P. Phosphatidycholine translocase: a physiological role for the mdr2 gene. Cell 1994; 77:1071-1081.
7. Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, Varadi A, Sarkadi B, Borst P. MDR3 P-glycoprotein, phosphatidycholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with neucleotide trapping. J Biol Chem 2000; 275:23530-23539.
8. Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters, Toxicology 2001; 167:3-23.
9. Zaman GJ, Flens MJ, van Leusden MR, de Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ. Human drug resistance associated protein MRP is a plasma membrane drug-efflux pump. Prod Natl Acad Sci 1994; 91:8822-8826.
10. Krishnamachary N, Center MS. MRP gene associated with a non-P-glycoprotein multidrug resistance encode a 190-kDa membrane bound glycoprotein. Cancer Res 1993; 53:3658-3661.
11. Xiao JJ, Foraker AB, Swaan PW, Liu S, Huang Y, Dai Z, Chen J, Sadee W, Byrd J, Marcucci G, Chan KK. Efflux of Depsipeptide FK228 (FR091228, NSC-630176) is mediated by both P-glycoprotein and MRP1. J Pharmacol EXP Ther 2005; 313:268-276.
12. Larkin A, O'Driscol L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M, Clynes M. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J cancer 2004; 112:286-294.
13. Letourneau IJ, Bowers RJ, Deeley RG, Cole SP. Limited modulation of the transport activity of the human multidrug resistance proteins MRP1, MRP2 and MRP3 by nicotine glucuronide metabolites. Toxicol Lett 2005; 157:9-19.
14. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 2000; 57:760-768.
15. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, SuZuki N, Tsuji A. Involvement of multidrug resistance associated protein 2 in intestinal secretion of grepafloxacin in rats. Antimicrob Agents Chemother 2002; 46:344-349.
16. Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I, William-Faltaos D, Fernandez C, Hatem S, Deray G, Komajda M, Leblond V, Lechat P. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005; 15:277-285.
17. Huisman MT, Smit JW, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. Crommentuyn KM et al. Multidrug resistance protein 2 (MRP2) transport HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002; 16:2295-2301.
18. Gottesman MM, Pastan I' Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev1996; 6:610-617.
19. Sharom FJ. P-glycoprotein efflux pump: how does it transport? J Membr Biol1997; 160: 161-175.
20. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE. Multidrug-resistant phenotype associated with over expression of the new ABC half transporter, MXR (ABCG2). J Cell Sci 2000; 113:2011-2021.
21. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39:361-98.
22. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42:59-98.
23. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999; 39:1203-1211.
24. Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. The role of half-transporters in multidrug resistance. J Bioenerg Biomembr 2001; 33:503-511.
25. Zhou S, Schuetz JD, Bunting KD. Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7:1028-1034.
26. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000; 92:1651-1656.
27. Kipp H, Arias IM. Intracellular trafficking and regulation of canalicular ATP-binding cassette transporters. Semin Liver Dis 2000; 20:339-351.
28. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci 1987; 84:7735-7738.
29. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A4 in limiting oral absorption of peptides and peptidomimectics. J Pharm Sci 1998; 87: 1322:1330.
30. Katragadda S. Budda B, Anand BS, Mitra AK. Role of efflux pumps and metabolizing enzymes in drug delivery. Expert Opin Drug Deliv 2005; 2:683-705.
31. Krishna DR, Koltz U. Extrahepatic metabolism of drugs in human. Clin Pharmacokinet 1994; 26:144-160.
32. Nelson DR. introductory remarks on human CYPs. Drug Metab Rev 2002; 34:1-5.
33. Evans WE, Relling MV. Pharmacogrnomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
34. Slaughter RL, Edwdards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995; 29:619-624.
35. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003; 43:149-173.
36. Zhao X, Imig JD. Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 2003; 4:73-84.
37. Liu M, Hurn PD, Alkayed NJ. Cytochrome P450 in neurological disease. Curr Drug Metab 2004; 5:225-234.
38. Watkins PB, Wrighton SA, Schuetz E.G, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80:1029-36.
39. Shen DD, Kunze KL, Thummel KE. Enzyme-catalyzed process of first-pass hepatic and intestinal drug extraction. Adv Drug Delivery Rev 1997; 27:99-127.
40. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P540IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90:1871-1878.
41. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB. Inter-patient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22:947-955.
42. Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001; 12:505-513.
43. Chiou WL, Chung SM, Wu TC. Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 2000; 17:903-905.
44. Osterberg T, Norinder U. Theoritical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics. Eur J Pharm Sci 2000; 10:295-303.
45. Chiba P, Ecker G, Schmid D, Drach J, Tell B, Goldenberg S, Gekeler V. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol Pharmcol 1996; 49:1122-1130.
46. Watkins PB. The barrier functions of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997; 27: 161-70.
47. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13: 129-134.
48. Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 2004; 11:262-277.
49. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ALB tyrosine kinase in chronic myeloid leukemia. N Eng J Med 2001; 344:1031-1037.
50. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Eng J Med 2002; 347:472-480.
51. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nature Rev/Cancer 2006; 6:546-558.
52. Martin-Facklam M, Burhenne J, Ding R, Fricker R, Mikus G, Walter-Sack I, Haefeli WE. Dose dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophore EL. Br J Clin Pharmacol 2002; 53:576-581.
53. Tayrouz Y, Ding R, Burhenne J, Riedel KD, Weiss J, Hoppe-Tichy T, Haefeli WE, Mikus G. Pharmacokinetic and pharmaceutic interaction between digoxin and cremophore RH40. Clin Pharmacol Ther 2003; 73:397-405.
54. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH. Reversal of multidrug resistance by surfactants. Br J Cancer 1992; 66:62-68.
55. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicle in taxane pharmacology. Invest New Drug 2001; 19:125-141.
56. Sonneveld P, Marie JP, Huisman C. Reversal of multidrug resistance by SDZ PSC 833 combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 1996; 10:1741-1750.
57. Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: Why are they important and can they be minimized? Crit Rev Oncol Hematol 2005; 55:117-142.
58. Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the invitro metabolism of dolassetrone. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 1996; 24:602-609.
59. Roche Laboratories. Kytril prescribing information. Roche (online), http://www.rocheusa.com/products/kytril/pi_tablets.pdf 2005.
60. Cagnoni PJ, Mathes S, Day TC, Bearman SI, Shpall EJ, Jones RB. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999; 24:1-4.
61. Gilbert CJ, Petros WP, Vredenburgh J, Hussein A, Ross M, Rubin P, Fehdrau R, Cavanaugh C, Berry D, McKinstry C, Peters WP. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy of breast cancer. Cancer Chemother Pharmacol 1998; 42:497-503.
62. Dixon CM, Colthuo PV, Serabjit-Sing CJ, Boehlert CC, Park GR, Tarbit MH. Multiple forms of P450 are involved in the metabolism of ondanstron in humans. Drug Metab Dispos 1995; 23:1225-1230.
63. Nakamura H, Ariyoshi N, Okada K, Nakasa H, Nakazawa K, Kitada M. CYP1A1 is major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab 2005; 6:469-480.
64. Townsend DM, Deng M, Zhang L, Lapus MG, Haringan MH. Metabolism of cisplatin to a nephrotoxin in proximal tuble cells. J AM Soc Nephrol 2003; 14:1-10.
65. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 2000; 38:291-304.
66. Chang TK, Weber CF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and isofosphamide by cytochrome P450 2B and 3A in human liver microsomes. Cancer Res 1993; 53:5629-5637.
67. Leveque D, Maloisel F. Clinical pharmacokinetics of imatinib mesylate. In Vivo 2005; 19:77-84.
68. Novartis Pharmaceuticals Corporation. Gleevec product information. Norvatis [online], http://www.pharma.us.novartis.com/product/pi/pdf/ gleevec_tabs.pdf. 2005.
69. Frye RF, Fitzgerald SM, Laguttuta TF, Hruska, MW, Egorin MJ. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004; 76:223-229.
70. Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R, Seiberling M. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004; 290-294.
71. Veronese ML, Sun W, Giantonio B, Berlin J, Shults J, Davis L, Haller DG, O'Dwyer PJ. A phase II trial of gefitinib with fluorouracil, leucovorin, and irrinotecan in patients with colorectal cancer. Br J cancer 2005; 92:1846-1849.
72. Iacono LC, Furman WL, Crews KR, Panetta JC, Freeman BB, Daw NC, Stewart CF. Effect of gefitinib on the systemic disposition of intravenous irrinotecan (IRN) in pediatric patients with refractory solid tumors. J Clin Oncol 2004; 22:2011.
73. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004; 65:1485-1495.
74. Wierdl M, Wall A, Morton CL, Sampath J, Danks MK, Schuetz JD, Potter PM. Carboxylesterasemediated sensitization of human tumor cells to CPT-11 can not override ABCG2imediated drug resistance. Mol Pharmacol 2003; 64:279-288.
75. Arboix M, Paz OG, Colombo T, D'Incalci M. Multidrug resistance-reversing agents increase vinblastin distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. J pharmacol Exp Ther 1997; 281:1226-1230.
76. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 2004; 19:171-179.
77. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005; 4:e5-e8.
78. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 2002; 302:666-671.
79. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. Cardiac dysfunction in the transtuzumb clinical trials experience. J Clin Oncol 2002; 20:1215-1221.
80. Haas A, Anderson L, Lad T. The influence of aminoglycosides on nephrotoxicity of cis-diamminedichloroplatinum in cancer patients. J Infect Dis 1983; 147:363.
81. Christensen ML, Stewart CF, Crom WR. Evaluation of aminoglycoside disposition in patients previously treated with cisplatin. Ther Drug Monit 1989; 11:631-636.
82. Bergstrom P, Johnsson A, Cavallin-Stahl E, Bergenheim T, Henriksson R. Effect of cisplatin and amphotericin B on DNA adduct formation and toxicity in malignant glioma and normal tissues in rat. Eur J Cancer 1997; 33:153-159.
83. Genentech, Inc. Rituxan product information. Genentec [online], http://www.gene.com/gene/product/information/pdf/rituxan-prescribing.pdf 2001.
84. Scalone S, Sorio R, Bortolussi R, Lombardi D, La Mura N, Veronesi A. Vinorelbine-induced acute reversible peripheral neuropathy in patient with ovarian carcinoma pretreated with carboplatin and paclitaxel. Acta Oncol 2004; 43:209-211.
85. Parimoo D, Jeffers S, Muggia FM. Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst 1996; 88:1079-1080.
86. Schwartz JD, Howard W, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDs-related Kaposi's sarcoma. Aids 1999; 13:283-284.
87. Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004.
88. Mummaneni V, Randall D, Chabuel D, Steady state pharmacokinetic (PK) interaction study of atazanavir (ATV) with clarithromycin (CLR) in healthy subjects. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30; San Diego, California. 2002; Abs. #H-1717.
89. Norvir [package insert] 2005; North Chicago, IL: Abbott Laboratories.
90. Fortovase [package insert] 2003; Basel, Switzerland: F. Hoffman-La Roche Ltd.
91. Boruchoff SE, Sturgill MG, Grasing KW, Seibold JR, McCrea J, Winchell GA, Kusma SE, Deutsch PJ. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. Clin Pharmacol Ther 2000; 67:351-59.
92. Foulds G, LaBoy-Goral L, Wei GC, Apseloff G. The effect of azithromycin on the pharmacokinetics of indinavir. J Clin Pharmacol 1999; 39:842-846.
93. Kaletra [package insert] 2005; North Chicago, IL: Abbott Laboratories; Oct.
94. Fiske W, Benedek IH. Pharmacokinetics of efavirenz (EFV) and ritonavir (RIT) after multiple oral doses in healthy volunteers.12th International Conference on AIDS; June 28-July 3; Geneva, Switzerland.1998; Abst. #42269.
95. Ouellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, Leonard JM. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 1998; 64: 355-62.
96. Aptivus [package insert] 2005; Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov.
97. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998; 87:803-807.
98. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. August 13. 2001.
99. Reyataz [package insert], Princeton, NJ: Bristol-Myers Squibb Company; Jan. 2006.
100. Agarwala S, Mummaneni V, Randall D. Pharmacokinetic effect of rifabutin on atazanavir with and without ritonavir in healthy subjects. 9th Conference on Retroviruses and Opportunistic Infections; Feb 24-28; Seattle, Washington 2002; Abst #445.
101. CDC Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2000, Jan 28, [AIDS Treatment Information Service: Current Treatment] Available at: http://www.hivatis.org/trtgdlns.html.
102. Crixivan [package insert] 2005; Whitehouse Station, NJ: Merck & Co., Inc.; Oct.
103. Hamzeh F, Benson C, Gerber J. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. 7th Conference on Retroviruses and Opportunistic Infections; Jan 30-Feb 2; San Francisco, California. 2000; Abst #90.
104. Viracept [package insert] 2004; La Jolla, CA: Agouron Pharmaceuticals, Inc.; Sept.
105. Cato A, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998; 63:414-421.
106. Burger D, Agarwala S, Child M. Effect of rifampin on steady-state pharmacokinetics of atazanavir and ritonavir in healthy subjects 12th Conference on Retroviruses and Opportunistic Infections; February 22-25; Boston, Massachusetts.2005; Abst #657.
107. Polk RE, Crouch MA, Israel DS, Pastor A, Sadler BM, Chittick GE, Symonds WT, Gouldin W, Lou Y. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy 1999;19:1378-384.
108. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998;18:83-97.
109. Grub S, Bryson H, Goggin T, Ludin E, Jorga K. The interaction of saquinavir with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 2001; 57: 115-121.
110. Sporanox [package insert] 2000; Titusville, NJ: Janssen Pharmaceutica.
111. Cardiello PG, Samor T, Burger D, Hoetelmans R, Mahanontharit A, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P. Pharmacokinetics of lower doses of saquinavir soft-gel caps boosted with itraconazole in HIV-1 positive patients. Antivir Ther 2003; 8:245-9.
112. Bellibas SE. Indinavir-fluconazole interaction. [letter] Antimicrob Agents Chemother 1999; 43:432-33.
113. De Wit S, Debier M, De Smet M, McCrea J, Stone J, Carides A, Matthews C. Deutsch P, Clumeck N. Effect of fluconazole on indinavir pharmacokinetics in human immuno-deficiency virus-infected patients. Antimicrob Agents Chemother 1998; 42:223-227.
114. Koks CH, Crommentuyn KM, Hoetelmans RM, Burger DM, Koopmans PP, Mathot RA, Mulder JW, Meenhorst PL, Beijnen JH.Koks CH, Crommentuyn KM, Hoetelmans RM. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1 infected individuals. Br J Clin Pharmacol 2001; 51:631-635.
115. OSI Pharmaceuticals Inc. & Genentech Inc; Tarceva prescribing information: Genentec 2005; [online], http://www.gene.com/gene/products/ information/oncology/tarceva/insert.jsp.
116. Kobayashi K, Ratain MJ, Fleming GF, Vogelzang NJ, Cooper N, Sun BL. A phase I study of CYP3A4 modulation of oral etoposide with ketoconazole in patients with advanced cancer. Proc. Am Soc Clin Oncol 1996; 15: Abstract # 1489.
117. Swaisland H, Smith RP, Farebrother J, Laight A. The effect of the induction and inhibition of CyP3A4 on the pharmacokinetics of single oral dose of ZD1839(Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK) in healthy male volunteers. Proc. Am Soc Clin Oncol 2002; 21: Abstract # 83.
118. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L. Atrovastatin co-administration may increase digoxin concentration by inhibition of intestinal P-glycoprotein mediated secretion. J Clin Pharmacol 2000; 14:1287-1289.
119. Bogman K, Peyer AK, Torok M, Kusters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001; 132:1183-1192.
120. Lexiva [package insert] 2005; Research Triangle Park, NC: Glaxo Wellcome Inc; Nov.
121. Carr RA, Andre AK, Bertz RJ. Concomitant administration of ABT-378/ritonavir. Results in a clinically important pharmacokinectic interaction with atorvastatin but not pravastatin. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20; Toronto, Canada. 2000; Abst #1644.
122. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45:3445-3450.
123. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, Giermasz A, Jakobisiak M. Lovostatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res, 2000; 6:2044-2052.
124. Feleszko W, Zagozdzon R, Golab J, Jakobisiak M. Potentiated antitumor activity effects of cisplatin and lovostatin against MmB16 melanoma in mice. Eur J Cancer 34:406-411.
125. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999; 5:2223-2229.
126. Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 2001; 1:141-149.
127. Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int J Oncol 2003; 23:1055-1069.
128. Piscitelli S.C., Burstein A.H., Chaitt D., Alfaro R.M., Falloon J. Indinavir concentrations and St John's wort. Lancet 2000 a; 355(9203): 547-548.
129. Piscitelli S.C., Burstein A.H., Welden N., Gallicano K.D., Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34:234-8.
130. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH.St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000; 67:451-457.
131. Chieli E, Romiti N, Cervelli F, Tongiani R. Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. Life Sci 1995; 57:1741-1751.
132. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, Ferrandina G, Piantelli M, Bussa S, Rumi C, Cianfriglia M. Quercetin potentiates the effect of adriamycin in a multidrugresistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 1994; 34: 459-464.
133. Shapiro AB, Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 1997; 53:587-596.
134. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604.
135. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001; 134:1601-1608.
136. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355 (9203):548-549.
137. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002; 53:75-82.
138. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 2004; 18:262-276.
139. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J. Drug interaction of St John's wort with cyclosporin. Lancet 2000a; 355(9218):1912.
140. Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000; 33:853-855.
141. Yue QY, Bergquist C, Gerden B. Safety of St John's wort (Hypericum perforatum). Lancet 2000; 355(9203): 576-577.
142. Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002; 32: 451-478.
143. Mathijssen RH, verweij J, de Bruijn P, loos WJ, Sparreboom A. Effect of St John's wort on the irinotecan metabolism. J Natl Cancer Inst 2002; 94:1247-1249.
144. Ciotti M, Basu N, Brangi M, Owens IS. Glucuronidation of 7-ethyl-10-hydroxycampothecin (SN-38) by human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 1999; 260:199-202.
145. Santose A. Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, Vassal G. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000; 6:2012-2020.
146. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y.1998.Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50:387-412.
147. Agrosi M, Mischiatti S, Harrasser PC, Savio D. 2000.Oral bioavailability of active principles from herbal products in humans. A study on Hypericum perforatum extracts using the soft gelatin capsule technology. Phytomedicine 2000; 7:455-462.
148. Biber A, Fischer H, Romer A, Chatterjee SS. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry, 1998; 31 Suppl 1: 36-43.
149. Guo LQ, Taniguchi M, Xiao YQ, Baba K, Ohta T, Yamazoe Y. Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity. Jpn J Pharmacol 2000; 82:122-129.
150. Ameer B, Weintraub RA. Drug interactions eith grapefood juice. Clin Pharmacokinetics 1997; 33:103-121.
151. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmcol Ther 1995; 58:127-131.
152. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294:88-95.
153. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003; 73: 41-50.
154. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70:317-26.
155. Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA..Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 2001; 60:427-431.
156. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97: 7500-7502.
157. Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166:R11-16.
158. Bray BJ, Perry NB, Menkes DB, Rosengren RJ. St. John's wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. Toxicol Sci 2002; 66:27-33.
159. Wynn GH, Cozza, KL, Zapor MJ, Wortmann, GW, Armstrong SC. Antiretrovirals, Part III: Antiretrovirals and Drugs of Abuse. Psychomatics 2005; 46:79-87.
160. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf J, Mertzanis P, Hoffman JL, Shader RI. Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther 2000; 67:335-341.
161. Venkatakrishnan K, Greenblatt DJ, von Molkte LL, Shader RI. l Alprazolam is another substrate for human cytochrome P450-3A isoforms. J Clin Psychopharmacol 1998; 18:256.
162. Smith KM, Larive LL, Romanelli F. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health Syst Pharm 2002; 59:1067-1076.
163. Ladona MG, Gonzalez ML, Rane A, Peter RM, de la Torre R. Cocaine metabolism in human fetal and adult liver microsomes is related to cytochrome P450 3A expression. Life Sci 2000; 68:431-443.
164. LeDuc BW, Sinclair PR, Shuster L, Sinclair JF, Evans JE, Greenblatt DJ. Norcocaine and Nhydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3A4. Pharmacology 1993; 46:294-300.
165. Bornheim L. Effect of cytochrome P450 inducers on cocaine-mediated hepatotoxicity. Toxicol Appl Pharmacol 1998;150:158-165.
166. Pellinen P, Honkakoski P, Stenbeck F, Niemitz M, Alhava E, Pelkonen O, Lang MA, Pasanen M. Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur J Pharmacol 1994; 270:35-43.
167. Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999; 159:2221-2224.
168. Pau AK. Polypharmacy problems: Drug interactions in multidrug therapy of HIV infection. 2002; www.hiv-druginteractions.org
169. Henry J, Hill I. Fatal interaction between ritonavir and MDMA. Lancet 1998; 352:1751-1752.
170. Lin LY, Di Stefano EW, Schmitz DA, Hsu L, Ellis SW, Lennard MS, Tucker GT, Cho AK. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos 1997; 25:1059-1064.
171. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ("Ecstasy"). Toxicol Lett 2000; 112/113:133-142.
172. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R. Roset PN, Segura J, Cami J. Non-linear pharmacokinetics of MDMA ("Ecstasy") in humans. Br J Clin Pharmacol 2000; 49:104-109.
173. Ketabi-Kiyanvash N, Weiss J, Haefeli WE, Mikus G. P-Glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine, and paramethoxyamphetamine. Addict Biol 2003; 8:413-418.
174. 8- tetrahydrocannabinol in human liver microsomes. Drug Metab Dispos 2000; 28:1291-1296.
175. Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, Abrams DI.The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002; 16:543-550.
176. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 2003; 139:258-266.
177. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics 2003a; 44:167-171.
178. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part II. Psychosomatics2003b; 44:515-520.
179. Piscitelli SC, Kress DR, Bertz RJ, Pau A, Davey R. The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. Pharmacotherapy 2000b; 20:549-553.
180. Schwartz EL, Brechbuhl AB, Khal P. Pharmacokinetic interactions of Zidovudine and methadone in intravenous drug-using patients with HIV infections. J Acquir Immune Defic Syndr 1992; 5:619-626.
181. McCance-Katz EF, Rainey PM, Jatlow P, Friedland GH. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr 1998; 18:435-443.
182. Stazewski S, Haberl A, Gute P. Nevirapine/didanosine/lavivudine once daily in HIV-1-infected intravenous drug users. Antivir Ther 1998; 3 (suppl 4):55-56.
183. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999;13:957-962.
184. Beauverie P, Taburet AM, Dessalles MC, Furlan V, Touzeau D. Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors (letter). AIDS 1998; 12:2510-2511.
185. Pinzani V, Faucherre V, Peyreire H, Blayac JP. Methadone withdrawal symptoms with nevirapine and efavirenz (letter). Ann Pharmacother 2000; 34:405-407.
186. McCance-Katz FF, Rainey PM, Jatlow P, Friedland GH. Methadone effects on zidovudine disposition (AIDS Clinical Trial Group 262). J Acquir Immune Defic Syndr 1998; 18:435-443.
187. Bart PA, Rizzardi PG, Gallant S, Golay KP, Baumann P, Pantaleo G, Eap CB. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit 2001; 23:553-555.
188. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9:365-373.
189. Wu D, Otton SV, Sproule BA. Inhibition of cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmac Ther 1993; 35:30-34.
190. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampicin induced methadone withdrawl. N Eng J Med 176; 294:1104-1106.
191. Brown LS, Sawyer RC, Li R, Cobb MN, Colborn DC, Narang PK. Lack of pharmacologic interaction between rifabutin and methadone. Drug Alcohol Depend 1996; 43:71-77.
192. Cobb M, Desai J, Brown LS. The effect of fluconazole on the clinical pharmokinetics of methadone. Clinical Pharmacol Ther 1998; 63:655-662.
193. Gourevitch MN, Friedland GF. Methadone and antiretroviral medications, Parts 1 & 2. AIDS Clin Care 1999; 11:30-31 and 37-46.
194. Greiner B, Eichelbaum M, Fritz P. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104:147-53.
195. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P450 3A4 in mice and humans. Proc Natl Acad Sci USA 1996; 93:4001-4005.
196. Penzak S, Shen J, Alfar R, Remaley A, Falloon J. Influence of low-dose ritonavir on the pharmacokinetics of the P-glycoprotein (P-gp) substrate digoxin. Program and abstracts of the 4th International Workshop on Clinical Pharmacology of HIV Therapy 2003; March 27-29, Cannes, France. Abstract 2.6.
197. Brinkman K, Huysmans F, Burger DM.l Pharmacokinetic interaction between saquinavir and cyclosporine. Ann Intern Med 1998; 129:914-915.
198. Ieiri I, Takane H, Ostubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004; 43:553-576.
199. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol. 2005; 45:477-94.
200. Kim RB. MDR1 single neucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 2002; 12:425-427.
201. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant MDR1 alleles among European, Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
202. Chang GWM, Kam PC. The Physiological and pharmacological roles of P450 isoenzymes. Anaesthesia 1999; 54:42-50.
203. Wang A, Yu BN, Luo CH, Tan ZR, Zhou G, Wang LS, Zhang W, Li Z, Liu J, Zhou HH. IIe 118Val genetic polymorphism of Cyp3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 2005; 60:843-848.
204. van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein bloker SDZ PSC 833. Br J Cancer 1997; 76:1181-1183.
205. Morgan RG. Leucovorin enhancement of the effects of the fluoropyridines on thymidylate synthase. Cancer 1989; 63:1008- 1012.
206. Kohne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Ruckle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ; Randomized phase III study of high dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin verses bolus fluorouracil plus leucovorin in advanced colorectal cancer. European Organization of Research and Treatment of Cancer Gastrointestional Group Study 40952. J Clin Oncol 2003; 21:3721-3728.
207. Shiloni E, Matzner Y. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethazone: does it reduce the antitumor therapeutic efficacy. Blood 1991; 78:1389-1390.
208. Mier JW. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethazone: prevention of acquired neutrophill chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990; 76:1933-1940.
209. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43(6), 630-5.
210. Rey JM, Walter G. Hypericum perforatum (St John's wort) in depression: pest or blessing? Med J Aust 1998; 169:583-586.
211. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000; 67:451-457.
212. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47:1969-1979.
213. Olesen OV, Linnet K. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology1997; 55:235-243.
214. Venkatakrishnan K, Schmider J, Harmatz JS, Ehrenberg BL, von Moltke LL, Graf JA, Mertzanis P, Corbett KE, Rodriguez MC, Shader RI, Greenblatt DJ. Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol 2001; 41:1043-1054.
215. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol 1999; 39:567-577.
216. Ha HR, Chen J, Freiburghaus AU, Follath F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39:321-326.
217. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27:866-871.
218. Tian R, Koyabu N, Takanaga H, Matsuo H, Ohtani H, Sawada Y. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res 2002; 19: 802-809.
219. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73:67-74.
220. Kim AE, Dintaman JM, Waddell DS, Silverman JA. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998; 286:1439-1445.
221. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423-431.
222. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31:469-497.
223. Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997; 25:1347-1353.
224. Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 2003; 73: 223-231.
225. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96:1698-1705.
226. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38:389-430.
227. Bogman K, Peyer AK, Torok M, Kusters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001; 132:1183-1192.
228. Barbenel DM, Yusufi B, O'Shea D, Bench CJ. Mania in a patient receiving testosterone replacement postorchidectomy taking St John's wort and sertraline. J Psychopharmacol 2000; 14:84-86.
229. Beckman SE, Sommi RW, Switzer J. Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability. Pharmacotherapy 2000; 20:568-574.
230. Dannawi M. Possible serotonin syndrome after combination of buspirone and St John's Wort. J Psychopharmacol 2002; 16:401.
231. Gordon JB. SSRIs and St.John's Wort: possible toxicity? Am Fam Physician 1998; 57: 950-953.
232. Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999: 12:7-10.
233. Parker V, Wong AH, Boon HS, Seeman MV. Adverse reactions to St John's Wort. Can J Psychiatry 2001; 46: 77-79.
234. Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S, Scholler G, Langheinrich M, Roots I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum ). J Clin Psychopharmacol 2002; 22:46-54.
235. Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj 2002; 16:359-367.
236. Maurer A JA, Bauer S. Interaction of St John's wort extract with phenprocoumon. Eur J Clin Pharmacol 1999; 55:22.
237. Ernst E. Second thoughts about safety of St John's wort. Lancet 1999; 354(9195):2014-2016.
238. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71:414-420.
239. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998; 87:803-807.
240. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997; 25: 256-266.
241. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 1999: 33:502.
242. Sarkar MA, Hunt C, Guzelian PS, Karnes HT. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos 1992; 20:31-37.
243. Kawaguchi A, Ohmori M, Tsuruoka S, Nishiki K, Harada K, Miyamori I, Yano R, Nakamura T, Masada M, Fujimura A. Drug interaction between St John's Wort and quazepam. Br J Clin Pharmacol 2004; 58:403-410.
244. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43:630-635.
245. Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann M W, Klempnauer J. Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum). Transplantation 2000b: 69:2229-2230.
246. Barone GW, Gurley BJ, Abul-Ezz SR. Herbal supplements: a potential for drug interactions in transplant recipients.Transplatation 2001; 71:239-241.
247. Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH, Roots I, and Mai I. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol 2003; 55:203-211.
248. Roots I. [Drug interactions with Hypericum. Is nature not so mild after all?. Interview by Petra Eiden]. MMW Fortschr Med 2000; 142:14.
249. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66:338-345.
250. Bon S, Hartmann K, Kubn M. Johanniskraut: ein enzymindultor? Schweitzer Apothekerzeitun 1999; 16:535-536.
251. Kim BR. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002; 34:47-54.
252. Oesterheld J. P-glycoprotein Table- the effect of drugs and foods. www.mhc.com/PGP.
253. Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Phar Ther 1998; 23:403-416.